Cargando…

Identification of Long Non-Coding RNAs Deregulated in Multiple Myeloma Cells Resistant to Proteasome Inhibitors

While the clinical benefit of proteasome inhibitors (PIs) for multiple myeloma (MM) treatment remains unchallenged, dose-limiting toxicities and the inevitable emergence of drug resistance limit their long-term utility. Disease eradication is compromised by drug resistance that is either present de...

Descripción completa

Detalles Bibliográficos
Autores principales:	Malek, Ehsan, Kim, Byung-Gyu, Driscoll, James J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5083923/ https://www.ncbi.nlm.nih.gov/pubmed/27782060 http://dx.doi.org/10.3390/genes7100084

Ejemplares similares

P844: CHARACTERIZATION OF MULTIPLE MYELOMA CELL LINES WITH ACQUIRED-RESISTANCE TO PROTEASOME INHIBITORS HIGHLIGHTS A LINK BETWEEN RESISTANCE AND METABOLIC DEREGULATION
por: De Boussac, H., et al.
Publicado: (2022)

Proteasome Inhibitors for the Treatment of Multiple Myeloma
por: Ito, Shigeki
Publicado: (2020)

Long Non-Coding RNAs in Multiple Myeloma
por: Nobili, Lucia, et al.
Publicado: (2018)

Long Non-Coding RNAs in Multiple Myeloma
por: Butova, Romana, et al.
Publicado: (2019)

Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits
por: Acosta-Alvear, Diego, et al.
Publicado: (2015)

Novel mechanism of drug resistance to proteasome inhibitors in multiple myeloma
por: Zhou, Jianbiao, et al.
Publicado: (2019)

SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma
por: Heynen, Guus J. J. E., et al.
Publicado: (2022)

Long non-coding RNAs in multiple myeloma (Review)
por: Yang, Chenbo, et al.
Publicado: (2023)

New proteasome inhibitors in the treatment of multiple myeloma
por: Hungria, Vania Tietsche de Moraes, et al.
Publicado: (2019)

MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma
por: Qiang, Ya-Wei, et al.
Publicado: (2018)

Tetrahydrobiopterin induces proteasome inhibitor resistance and tumor progression in multiple myeloma
por: Zhang, Hua, et al.
Publicado: (2022)

Metabolic Alterations in Multiple Myeloma: From Oncogenesis to Proteasome Inhibitor Resistance
por: Weir, Philip, et al.
Publicado: (2023)

Identification of long intergenic non-coding RNAs (lincRNAs) deregulated in gastrointestinal stromal tumors (GISTs)
por: Gyvyte, Ugne, et al.
Publicado: (2018)

Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma
por: Gu, Yanyan, et al.
Publicado: (2020)

Identification of novel long non-coding RNAs deregulated in hepatocellular carcinoma using RNA-sequencing
por: Esposti, Davide Degli, et al.
Publicado: (2016)

Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma
por: Merin, Noah M., et al.
Publicado: (2014)

Ixazomib: An Oral Proteasome Inhibitor for the Treatment of Multiple Myeloma
por: Ramirez, Krista G.
Publicado: (2017)

Acquisition of a Multidrug Resistant Phenotype with a Proteasome Inhibitor in Multiple Myeloma
por: Gutman, Delia, et al.
Publicado: (2009)

Soluble and Cell–Cell-Mediated Drivers of Proteasome Inhibitor Resistance in Multiple Myeloma
por: Farrell, Mariah L., et al.
Publicado: (2018)

Therapeutic implications of mitochondrial stress–induced proteasome inhibitor resistance in multiple myeloma
por: Sharma, Aditi, et al.
Publicado: (2022)

Exploration of Deregulated Long Non-Coding RNAs in Association with Hepatocarcinogenesis and Survival
por: Shen, Jing, et al.
Publicado: (2015)

Correlation of long non-coding RNA expression with metastasis, drug resistance and clinical outcome in cancer
por: Malek, Ehsan, et al.
Publicado: (2014)

Oral proteasome inhibitor with strong preclinical efficacy in myeloma models
por: Park, Jonghoon, et al.
Publicado: (2016)

Modulating proteasome inhibitor tolerance in multiple myeloma: an alternative strategy to reverse inevitable resistance
por: Ge, Maolin, et al.
Publicado: (2020)

The Mitochondrial Protease LonP1 Promotes Proteasome Inhibitor Resistance in Multiple Myeloma
por: Maneix, Laure, et al.
Publicado: (2021)

Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors
por: Schwestermann, Jonas, et al.
Publicado: (2022)

Proteasome inhibitors – molecular basis and current perspectives in multiple myeloma
por: Kubiczkova, Lenka, et al.
Publicado: (2014)

The Landscape of Signaling Pathways and Proteasome Inhibitors Combinations in Multiple Myeloma
por: Paradzik, Tina, et al.
Publicado: (2021)

Geranylgeranyl diphosphate synthase inhibitor and proteasome inhibitor combination therapy in multiple myeloma
por: Haney, Staci L., et al.
Publicado: (2022)

A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma
por: Mitra, A K, et al.
Publicado: (2017)

Sec61 blockade therapy overrides resistance to proteasome inhibitors and immunomodulatory drugs in multiple myeloma
por: Domenger, Antoine, et al.
Publicado: (2023)

A compendium of long non-coding RNAs transcriptional fingerprint in multiple myeloma
por: Ronchetti, Domenica, et al.
Publicado: (2018)

Novel Agents for the Treatment of Multiple Myeloma: Proteasome Inhibitors and Immunomodulatory Agents
por: Kurtin, Sandra E., et al.
Publicado: (2013)

Pulmonary Nocardiosis in a Multiple Myeloma Patient Treated with Proteasome Inhibitors
por: Mendonca, Nikolai P., et al.
Publicado: (2016)

The Effects of Proteasome Inhibitors on Telomerase Activity and Regulation in Multiple Myeloma Cells
por: Shalem-Cohavi, Naama, et al.
Publicado: (2019)

Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma
por: Chen, John H., et al.
Publicado: (2017)

Deregulation and Targeting of TP53 Pathway in Multiple Myeloma
por: Jovanović, Katarina K., et al.
Publicado: (2019)

Genetic Alterations in Members of the Proteasome 26S Subunit, AAA-ATPase (PSMC) Gene Family in the Light of Proteasome Inhibitor Resistance in Multiple Myeloma
por: Haertle, Larissa, et al.
Publicado: (2023)

microRNA dependent and independent deregulation of long non-coding RNAs by an oncogenic herpesvirus
por: Sethuraman, Sunantha, et al.
Publicado: (2017)

Predicting Successful Phase Advancement and Regulatory Approval in Multiple Myeloma From Phase I Overall Response Rates
por: Malek, Ehsan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_sfhsmls1ne6girg18dipfo4qb0